Heart Failure Risk with Onglyza, Similar Diabetes Drugs Lead to FDA Warnings
Onglyza and similar diabetes drugs may increase the risk of heart failure, according to an FDA warning that will lead to new label warnings being added to the drugs.
Onglyza and similar diabetes drugs may increase the risk of heart failure, according to an FDA warning that will lead to new label warnings being added to the drugs.
The FDA has launched an investigating into the possibility that diabetics may face an increased risk of pancreatitis and pancreatic cancer from an entire class of diabetes drugs, which includes…
As sales of the brand-name version of the diabetes drug Actos continue fall amid mounting injury lawsuits and recent generic competition, Takeda Pharmaceuticals has launched a trio of new drugs…